Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Rosseti South reported its 2022 IFRS results

3/22/23 MRKY

IDGC of North-West reported for 2022 according to IFRS

3/22/23 MRKZ

IDGC of Urals reported for 2022 according to IFRS

3/22/23 MRKU

Berkeley Lights and IsoPlexis have completed their merger

3/22/23 CELL

VTB's additional issue will be bought by pension funds

3/22/23 VTBR

The ANTA Sports Products announced a final dividends for 2022

3/22/23 2020

Nike reported for 9 months of fiscal year 2023

3/22/23 NKE

FAS allowed Bashinformsvyaz to consolidate 100% of JV with Lukoil

3/22/23 BISVP

The JPMorgan Chase & Co announced a quarterly dividend

3/21/23 JPM

MTS will offer business and premium customers communication services based on the MVNO model

3/21/23 MTSS